Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
|Articles|July 27, 2022
Daily Medication Pearl: Angiotensin II (Giapreza) Injection
Author(s)Saro Arakelians, PharmD
Angiotensin II (Giapreza) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
Advertisement
Medication Pearl of the Day: Angiotensin II (Giapreza) Injection
Indication: Angiotensin II (Giapreza) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
Insight:
- Dosing: Start angiotensin II intravenously at 20 nanograms (ng)/kg/min. Titrate as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed. During the first 3 hours, the maximum dose should not exceed 80 ng/kg/min. Maintenance dose should not exceed 40 ng/kg/min.
- Dosage forms: Injection 2.5 mg/mL and 5 mg/2 mL (2.5 mg/mL) in a vial.
- Adverse events: The most common adverse reactions reported in greater than 10% in patients administered angiotensin II were thromboembolic events.
- Mechanism of action: Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca2+/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.
Source:
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Two Gene Therapy Approvals Expand Options for Rare Immune Disorders as Access Challenges Persist
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
RSV Hospitalization Linked to Higher Short-Term Risk of Invasive Pneumococcal Disease
5